On Tuesday, Australia’s Therapeutic Goods Administration (TGA) announced a raft of changes to how products containing vitamin B6 are packaged and sold.
The TGA decision is based on an extensive review, prompted by widespread concerns earlier this year that high doses were causing toxicity and leading to lasting nerve damage.
